PI3K/5‐LOX/LTB4 axis sheds light on the promising future of synergistic treatment regimen of targeted therapy and immunotherapy for LBC patients. Here, ALOX5 is linked to CDH1-related diffuse gastric and lobular breast cancer syndrome.